The University of Pittsburgh Alzheimer Disease Research Center (ADRC) is one of the nation's leading research centers specializing in the diagnosis of Alzheimer's disease and related disorders. Through outpatient evaluations, participants and their families receive state-of-the-art diagnostic assessments and contribute to the scientific study of Alzheimer's disease

Learn More »

Our memory evaluation is an extensive diagnostic evaluation of individuals with suspected Alzheimer's disease and other types of memory loss and/or cognitive impairment. The professionals at the ADRC understand that this is a stressful process for all and assure that individuals will be treated with sensitivity and respect.

Learn More »

The ADRC is currently recruiting participants
for these clinical trials:

    Dementia with Lewy Bodies Consortium

    Description: The purpose of this study is to collect clinical information, brain imaging scans, and biological samples from people that have dementia with Lewy bodies. This information will help researchers improve the diagnosis, care, and treatment of patients with this disease.

    Study Length: 5 years

    Study Requirements
    • Age 40-90
    • Diagnosis of Lewy Body Dementia (DLB) or high likelihood
    • A study partner who will accompany you to all study visits
    Contact:
    Donna Simpson at 412-692-2717 or simpsondm@upmc.edu or
    MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu
    Alzheimer's Disease Neuroimaging Initiative - 3 (ADNI3)

    Description: The overall goal is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD) from its earliest stages. Subjects will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans and cerebral spinal fluid (CSF) collection. For more information about the ADNI3 study visit http://www.adni-info.org/

    Study Length: up to 5 years

    Study Requirements
    • 55-90 years of age
    • Cognitively normal; or have Mild Cognitive Impairment (MCI); or have been diagnosed with Alzheimer’s disease
    • A study partner who will accompany you to all study visits
    Contact:
    MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu
    Sleep Study (Prefrontal Cortex Stimulation in MCI)

    Description: Previous research has shown that certain forms of brain stimulation can affect sleep patterns as well as cognitive function. The goal of this study is to test whether changes in sleep patterns with brain stimulation influence cognition in people with Mild Cognitive Impairment (MCI).

    Study Length: 14 days

    Study Requirements
    • Diagnosis of Mild Cognitive Impairment (MCI)
    • Age 60-85
    • Normal or corrected-to-normal visual and auditory acuity
    Contact:
    MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu
    Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD)

    Description: The study is designed to examine the efficacy and safety of escitalopram in combination with a psychosocial intervention (PSI) as treatment for agitation in AD patients.

    Study Length: 6 months

    Study Requirements
    • Diagnosis of Alzheimer’s disease with significant agitation/aggression
    • A study partner who will accompany you to all study visits
    Contact:
    Patricia Henderson 412-692-2703 or hendersonpl@upmc.edu or
    MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu


Top